ELISPOT Assay for Monitoring Cytotoxic T Lymphocytes (CTL) Activity in Cancer Vaccine Clinical Trials
Open Access
Abstract
The profiling and monitoring of immune responses are key elements in the evaluation of the efficacy and development of new biotherapies, and a number of assays have been introduced for analyzing various immune parameters before, during, and after immunotherapy. The choice of immune assays for a given clinical trial depends on the known or suggested immunomodulating mechanisms associated with the tested therapeutic modality. Cell-mediated cytotoxicity represents a key mechanism in the immune response to various pathogens and tumors. Therefore, the selection of monitoring methods for the appropriate assessment of cell-mediated cytotoxicity is thought to be crucial. Assays that can detect both cytotoxic T lymphocytes (CTL) frequency and function, such as the IFN-γ enzyme-linked immunospot assay (ELISPOT) have gained increasing popularity for monitoring clinical trials and in basic research. Results from various clinical trials, including peptide and whole tumor cell vaccination and cytokine treatment, have shown the suitability of the IFN-γ ELISPOT assay for monitoring T cell responses. However, the Granzyme B ELISPOT assay and Perforin ELISPOT assay may represent a more direct analysis of cell-mediated cytotoxicity as compared to the IFN-γ ELISPOT, since Granzyme B and perforin are the key mediators of target cell death via the granule-mediated pathway. In this review we analyze our own data and the data reported by others with regard to the application of various modifications of ELISPOT assays for monitoring CTL activity in clinical vaccine trials.Keywords
This publication has 63 references indexed in Scilit:
- Granzymes, cytotoxic granules and cell death: the early work of Dr. Jurg TschoppCell Death & Differentiation, 2011
- A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancerClinical and Experimental Medicine, 2011
- ELISpot for measuring human immune responses to vaccinesExpert Review of Vaccines, 2011
- Induction of CD8+T-Cell Responses Against Novel Glioma–Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant GliomaJournal of Clinical Oncology, 2011
- New flow cytometric assays for monitoring cell-mediated cytotoxicityExpert Review of Vaccines, 2010
- Cytolytic CD4 cells: Direct mediators in infectious disease and malignancyCellular Immunology, 2010
- Defective γδ T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patientsExperimental Hematology, 2009
- Application of a Flow Cytometric Cytotoxicity Assay for Monitoring Cancer Vaccine TrialsJournal of Immunotherapy, 2009
- Application of the Granzyme B ELISPOT Assay for Monitoring Cancer Vaccine TrialsJournal of Immunotherapy, 2006
- Quantitating cellular immune responses to cancer vaccinesSeminars in Oncology, 2003